Not to mention a 23.5 month-OS of 24% (vs. only 9% in the control arm) when the 2 Eastern European outliers are eliminated. This means real hope for patients.
Yup, it's an apples and orangutans comparison, which I'm sure will be noted in the CC.
And the 24% D+G OS remained steady for the last 8 months. Eliminating the 2 Eastern European outliers really improved the results, and hopefully will in GALAXY 2 too. This is getting more interesting!